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Abstract
A Pseudomonas aeruginosa highly resistant to carbapenems was
isolated in a neonatal intensive care unit in Palermo, Italy. The
strain was found to carry a novel VIM-type enzyme, classified as
VIM-14. The novel enzyme differs from VIM-4 in a G31S muta-
tion. VIM-14 was harboured in a class 1 integron with a new
organization. The integron carried the genes aac7, blaVIM-14,
blaOXA-20 and aac4 in that order.
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Carbapenems are among the most effective antimicrobial
agents commonly used for treatment of infections due to
P. aeruginosa. Carbapenem resistance resulting from produc-
tion of metallo-b-lactamases (MBLs) is possibly the most
important mechanism because these enzymes reduce suscep-
tibility to all beta-lactams, and over recent years VIM-type
producing P. aeruginosa isolates have become endemic in
many European countries, especially in the Mediterranean
area [1].
To date, nine transferable types of MBL mobile genes have
been detected and studied, including blaIMP, blaVIM, blaSPM,
blaGIM [2], blaSIM [3], blaKHM [4] and blaAIM (D. Yong, T. R.
Walsh, J. Bell, B. Ritchie, R. Pratt and M. A. Toleman, pre-
sented at the 46th Interscience Conference on Antimicrobial
Agents and Chemotherapy, Washington, DC, 25–28 October
2008), blaNDM [5] and blaDIM (L. Poirel, J. M. Rodriguez-Marti-
nez, N. Al Naiemi, Y. Debets-Ossenkopp and P. Nordmann,
presented at the 19th European Congress of Clinical Microbi-
ology and Infectious Diseases, Helsinki, Finland, 16–19 May
2009). These genes have been often carried on gene cas-
settes of class 1 integrons and conjugative plasmids. Both
blaIMP and blaVIM genes have been largely reported worldwide
from among clinical isolates of Gram-negative pathogens, all
other MBL genes being reported only sporadically [1,6].
A 1-year prospective study of multidrug-resistant Gram-
negative microorganisms was carried out in a neonatal inten-
sive care unit (NICU) in Palermo, Italy, within the framework
of an infection control programme. All the newborns admit-
ted to the NICU for at least 24 h (211 cases) were enrolled
in the study. All the imipenem-resistant P. aeruginosa isolates
from specimen types (34 isolates) were screened for possible
MBL production by the EDTA disk synergy test. Within the
34 P. aeruginosa strains, 12 different pulsotypes were identi-
fied by PFGE. Genomic DNA was prepared according to
previously described methods, digested by XbaI and sepa-
rated using a CHEF-DRIII apparatus (Bio-Rad). Only the
strains of pulsotype A (21 isolates) were MBL producing.
The remaining 11 pulsotypes proved to be sporadic. Among
the 21 isolates producing MBL that belong to the same puls-
otype we selected PSE PA210 for further investigation. All
these isolates were considered as colonizers and they did
not confer infection.
Antimicrobial susceptibility testing of PSE PA210 was per-
formed by both diffusion and microdilution tests and inter-
preted according to the latest EUCAST breakpoints [http://
www.eucast.org/clinical_breakpoints/version 1.1]. The isolate
was resistant to imipenem (64 mg/L), meropenem (32 mg/L),
cefotaxime (>128 mg/L), ceftazidime (64 mg/L), gentamicin
(64 mg/L) and amikacin (16 mg/L) but was intermediate to
aztreonam (4 mg/L), and susceptible to piperacillin (8 mg/L)
and ciprofloxacin (£0.06 mg/L).
The resistance to carbapenems was further investigated
with the MBL Etest (AB, Biomerieux, Solna, Sweden), which
showed an minimal inhibitory concentration MIC decrease
from >32 to 1 mg/L in the presence of EDTA. MBL produc-
tion was further confirmed by hydrolysis assays of crude
cell extracts obtained as previously described [7], which
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hydrolysed 100 lM imipenem at the rate of 4.94 · 10)8
mole/min/mg protein; the hydrolysis rate dropped to
7.2 · 10)10 when the sample was pre-incubated for 20 min
at 25C with EDTA 2 mM.
The presence of blaVIM or blaIMP resistance genes was
checked by PCR. The oligonucleotide primers used for the





The PCR conditions were: 94C 1 min, 55C 1 min and
72C 1 min, for 35 cycles. For direct sequencing, PCR prod-
ucts were purified using Quiagen microspin (Quiagen GmbH,
Hilden, Germany). We obtained a 523 bp amplification prod-
uct with blaVIM-specific primers, and no amplification product
with blaIMP-specific primers. Amplification of the entire blaVIM
determinant using primers VIM-CF (5¢-GCACCCACCCT-
CATGGAG) and VIM-CR (5¢-ATGCCGCATCTGCTACTC)
yielded an amplicon of 836 bp. Direct sequencing of both
strands confirmed the presence of an MBL, which, after
comparison with VIM-4, showed one amino-acid change,
namely G31S. The new enzyme has been termed VIM-14 at
http://www.lahey.org/studies The bla(VIM-14) sequence was
deposited in GenBank and the accession number is
AY635904.
The gene for bla(VIM-14) was cloned in the phagemid vec-
tor pPCR Script Cam SK+ (Stratagene, La Jolla, California,
CA, USA). The entire bla(VIM) gene was amplified by PCR
with the primers VIM-CF and VIM-CR. The PCR product
was ligated with the phagemid vector pPCR script Cam SK+,
endowed with a chloramphenicol resistance gene and a lac
promotor for gene expression. Ligated vectors were trans-
formed to E. coli XL10 ultracompetent cells by the ligation
kit polishing protocol (Stratagene). Transformants were
selected on LB agar plates with 30 mg/L of chloramphenicol
and 0.25 mg/L of imipenem and then checked by PCR. In the
E. coli XL10/pVIM-14 strain, the plasmid caused definite
increases in the MICs for imipenem (>16-fold), meropenem
(>8-fold) and all other beta-lactams tested (Table 1).
The presence of class-1 integrons was assessed using the
class-1 specific primers 5-CS and 3-CS designed to anneal to
the 5¢ and the 3¢ conserved regions [9]. The genetic struc-
ture of the MBL-containing integron was deduced by sepa-
rately amplifying the 5¢ and 3¢ sections by means of class-1
specific primers and those designed for the MBL gene, and
by a set of PCR reactions. Fig. 1 shows that the integron
from bla(VIM-14)-producing strain PA210 contained an aac7
gene (coding for a 6¢-N-aminoglycoside acetyltransferase I1),
blaVIM-14, blaOXA-20 (coding for a class D carbapenemase),
and an aac4 gene (coding for an aminoglycoside 6¢ acetyl-
transferase). The integron sequence was deposited in Gen-
Bank and the accession number is FJ445404.
To investigate the outer membrane permeability in PA210
we adopted the protocol of Trias and Nikaido [10], and our
strain showed a normal OprD content as compared with the
OprD) and OprD+ control strains (3A and 3B, respectively).
We also studied the presence of integrase and resolvase
genes of Tn5051, and the insertion element IsPA7 of In70
[11]. A characteristic 530 bp PCR product was amplified
from the isolate when screened with tnpRF/R primers. How-
ever, we did not obtain 1300 bp tnpAF/R products. This
would indicate that the Tn5051 transposon was present in
our isolate but the transposon is defective in self-mobiliza-
tion sequences. Using the primers ISPF1/R1 and ISPF2/R2,
designed to amplify the 3¢ and 5¢ pieces of IsPa7, respec-
tively, we obtained the right size of amplicons showing that
PSE PA210 also presents the insertion sequence IsPa7.
We also performed bacterial conjugation experiments by
using Escherichia coli J53 AzR and P. aeruginosa PAO1 as reci-
pient strains. All attempts at conjugation had failed, including
those involving electroporation. This supports the suggestion
that blaVIM-14 is bearing a non-conjugative/non-mobilizable
element.
TABLE 1. Minimal inhibitory concentration (MICs) of








Imipenem 64 <0.06 1
Meropenem 32 <0.06 0.5
Cefotaxime >128 0.12 8
Ceftazidime 64 0.12 8
Aztreonam 4 0.12 0.12
Piperacillin 8 0.5 2
Piperacillin/tazobac 8 1 2
Ciprofloxacin <0.06 0.12 0.12
intI1 aacA7 Vim-14 Oxa-20 aacA4 qacEΔ1
FIG. 1. Schematic representation of the integron with bla(Vim-14). Rectangles represent the gene, the arrows the direction of the gene, the filled
circle the 59 bp elements and the non-filled circle the core site.
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VIM-14 represents a further addition to the list of VIM
enzymes, being described once again from an isolate from a
Mediterranean country. The novel integron described also
represents a disquieting addition to our understanding of
how MBLs can spread in multiple ways. The insertion ele-
ment IsPA7 of In70 has been described as typical of MBL-
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